Keywords: |
unclassified drug; ibritumomab tiuxetan; rituximab; technetium 99m; animals; mice; antineoplastic activity; cytotoxicity; cell line, tumor; diagnostic imaging; capromab pendetide in 111; antibodies, monoclonal; immune response; transplantation, heterologous; receptor, erbb-2; drug half life; trastuzumab; indium 111; tositumomab i 131; radioisotopes; drug protein binding; isotope; copper 64; 1,4,7,10 tetraazacyclododecane 1,4,7,10 tetraacetic acid; gallium 68; radioisotope decay; drug conjugation; chelating agents; gallium 67; alemtuzumab; half-life; tomography, emission-computed; mammary neoplasms, experimental; antigen-antibody reactions; immunoglobulin fragments; antibody conjugate; immunoconjugates; pentetic acid; heterocyclic compounds, 1-ring; radioimmunodetection; monoclonal antibody b.72.3; yttrium 86; arcitumomab tc 99m; oncoscint; humans; priority journal; article; gallium 66
|